Rotavirus vaccines for children in developing countries: Understanding the science, maximizing the impact, and sustaining the effort

Vaccine

Volumn 30, Issue SUPPL. 1, 2012, Pages A1-

  Neuzil, Kathleen M ^a   Parashar, Umesh D ^b   Steele, A Duncan ^a  

^a PATH   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE;

COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DIARRHEA; DRUG EFFICACY; EDITORIAL; HUMAN; IMMUNOGENICITY; MORTALITY; POLIOMYELITIS; PRIORITY JOURNAL; ROTAVIRUS INFECTION; SCORING SYSTEM; TREATMENT OUTCOME; VACCINATION;

EID: 84860012313     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.108     Document Type: Editorial

References (31)

1. Patel M.M., Steele D., Gentsch J.R., Wecker J., Glass R.I., Parashar U.D. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 2011, 30(January (1 Suppl.)):S1-S5.
2. Richardson V., Parashar U., Patel M. Childhood diarrhea deaths after rotavirus vaccination in Mexico. N Engl J Med 2011, 365(August (8)):772-773.
3. Curns A.T., Steiner C.A., Barrett M., Hunter K., Wilson E., Parashar U.D. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010, 201(June (11)):1617-1624.
4. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362(January (4)):289-298.
5. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(August (9741)):606-614.
6. Zaman K., Anh D.D., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(August (9741)):615-623.
7. Rotavirus vaccines: an update. Wkly Epidemiol Rec 2009;84(December (50)):533-40.
8. Breiman R.F., Zaman K., Armah G., Sow S.O., Dang A.D., Victor J.C., et al. Analysis of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of an oral pentavalent rotavirus vaccine. Vaccine 2012, 30(Suppl. 1):A24-A29.
9. Sow S.O., Victor J.C., Tapia M.D., Ciarlet M., Diallo F., Kodio M., et al. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine 2012, 30(Suppl. 1):A71-A78.
10. Laserson K.F., Nyakundi D., Feikin D.R., Nyambane G., Cook E., Oyieko J., et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq, in Kenya, including among HIV-infected and HIV-Exposed infants. Vaccine 2012, 30(Suppl. 1):A61-A70.
11. Zaman K., Yunus M., Arifeen S.E., Azim T., Faruque A.S.G., Huq E., et al. Methodology and lessons learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh. Vaccine 2012, 30(Suppl. 1):A94-A100.
12. Cunliffe N., Bostock N., Bouckenooghe A., Chimpeni P., Neuzil K.M., Ngwira B., et al. Efficacy of the human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life. Vaccine 2012, 30(Suppl. 1):A36-A43.
13. Madhi S.A., Louw C., Bos P., Aspinall A., Bouckenooghe A., Neuzil K.M., et al. Efficacy and immunogenicity of two or three dose rotavirus vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized double-blind placebo-controlled trial. Vaccine 2012, 30(Suppl. 1):A44-A51.
14. Feller A., Zaman K., Lewis K., Hoosain I., Yunus M., Sack D.A. Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age, following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh. Vaccine 2012, 30(Suppl. 1):A101-A105.
15. Armah G.E., Breiman R.F., Tapia M.D., Dallas M.J., Neuzil K.M., Binka F.N., et al. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine 2012, 30(Suppl. 1):A86-A93.
16. Shin S., Dang A.D., Zaman K., Yunus M., Le T.P.M., Thiem V.D., et al. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia - Bangladesh and Vietnam. Vaccine 2012, 30(Suppl. 1):A106-A113.
17. Patel M., Steele A.D., Parashar U. Influence of Oral Polio Vaccine (OPV) on performance of the monovalent and pentavalent rotavirus vaccines. Vaccine 2012, 30(Suppl. 1):A30-A35.
18. Lewis K., Dallas M.J., Victor J.C., Ciarlet M., Mast C.T., Ji M., et al. Comparison of two clinical severity scoring systems in multi-center, developing country rotavirus vaccine trials in Africa and Asia. Vaccine 2012, 30(Suppl. 1):A159-A166.
19. Feikin D.R., Laserson K.F., Ojwando J., Nyambane G., Ssempija V., Audi A., et al. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine 2012, 30(Suppl. 1):A52-A60.
20. Tapia M.D., Armah G.E., Breiman R.F., Dallas M.J., Lewis K.D.C., Sow S.O., et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine 2012, 30(Suppl. 1):A79-A85.
21. Cherian T., Wang S., Mantel C. Rotavirus vaccines in developing countries: the potential impact, implementation challenges and remaining questions. Vaccine 2012, 30(Suppl. 1):A3-A6.
22. Atherly D., Lewis K., Tate J., Parashar U., Rheingans R.D. Projected health and economic impact of rotavirus vaccination in GAVI eligible countries: 2011-2030. Vaccine 2012, 30(Suppl. 1):A7-A14.
23. Rheingans R.D., Atherly D., Anderson J. Distributional impact of rotavirus vaccination in GAVI eligible countries: estimating disparities in benefits and cost-effectiveness. Vaccine 2012, 30(Suppl. 1):A15-A23.
24. Tate J., Steele A.D., Bines J.E., Zuber P., Parashar U. Research priorities regarding rotavirus vaccines and intussusception: a meeting summary. Vaccine 2012, 30(Suppl. 1):A179-A184.
25. Steele A.D., Patel M., Cunliffe N., Breesee J.S., Borgstein E., Parashar U. Anticipating rotavirus vaccines in African children: summary of a workshop on intussusception in African countries. Vaccine 2012, 30(Suppl. 1):A185-A189.
26. Lloyd-Johnson C., Justice F., Donath S., Bines J.E. Retrospective hospital based surveillance of intussusception in children in a sentinel paediatric hospital: benefits and pitfalls for use in postmarketing surveillance of rotavirus vaccines. Vaccine 2012, 30(Suppl. 1):A190-A195.
27. Banyai K., Laszlo B., Vojdani J., Steele A.D., Nelson A., Gentsch J., et al. Systematic review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era: insights for understanding the impact of rotavirus vaccination programs. Vaccine 2012, 30(Suppl. 1):A122-A130.
28. Miles M., Lewis K., Kang G., Parashar U., Steele A.D. A systematic review of rotavirus strain diversity in India, Bangladesh, and Pakistan. Vaccine 2012, 30(Suppl. 1):A131-A139.
29. Nakagomi T., Nakagomi O., Dove W., Doan Y.H., Witte D., Ngwira B., et al. Molecular characterization of rotavirus strains detected during a clinical trial of a human rotavirus vaccine in Blantyre, Malawi. Vaccine 2012, 30(Suppl. 1):A140-A151.
30. Donato C., Cannan D., Bogdanovic-Sakran N., Snelling T.L., Kirkwood C. Characterization of a G9P[8] rotavirus strain identified during a gastroenteritis outbreak in Alice Springs, Australia post Rotarix vaccine introduction. Vaccine 2012, 30(Suppl. 1):A152-A158.
31. Dang A.D., Nguyen T.V., Vu T.D., Nguyen H.T., Nguyen M.D., Wang Y., et al. A dose escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children. Vaccine 2012, 30(Suppl. 1):A114-A121.